Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Adaptive Response to Intervention (RTI) for Students With ADHD
NCT03511976 · Florida International University · PHASE4 · withdrawn · last registry update 2025-08-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Death of PI” | – | Registry record, Florida International University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC6A3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-06Results posted on the registry: Yale University, Lisdexamfetamine Dimesylate (Medication) (NCT04599504)
- 2026-07-17Results posted on the registry: University of California, San Francisco, Bupropion (NCT03950427)
- 2026-07-07Also stopped (withdrawn): Mayo Clinic, Standard Varenicline Dosing (1 mg BID) + Bupropion 150 mg twice daily (NCT07171112)
- 2026-07-02Results posted on the registry: VA Office of Research and Development, Bupropion (NCT03978442)
- 2026-07-02Results posted on the registry: UCB BIOSCIENCES, Inc., midazolam + metformin (NCT06679413)
- 2026-07-02Results posted on the registry: Cingulate Therapeutics, CTx-1301 - Dexmethylphenidate 25mg + CTx-1301 - Dexmethylphenidate 37.5mg (NCT05631626)
- 2026-06-30Results posted on the registry: Zevra Therapeutics, Serdexmethylphenidate (NCT05668754)
- 2026-06-25Results posted on the registry: Axsome Therapeutics, Inc., AXS-05 (dextromethorphan-bupropion) (NCT06736509)
- 2026-06-25Also stopped (terminated): Axsome Therapeutics, Inc., AXS-05 (dextromethorphan-bupropion) (NCT06736509)
- 2026-06-11Results posted on the registry: University of California, Los Angeles, a drug against SLC6A3 (NCT05162391)
- 2026-06-03Results posted on the registry: University of Utah, Progesterone + Placebo (NCT05128071)
- 2026-05-27Results posted on the registry: University of Washington, a drug against SLC6A3 (NCT06027814)
- 2026-05-22Results posted on the registry: Boehringer Ingelheim, BI 1569912 + Repaglinide (NCT06367153)
- 2026-05-12Phase 3 first posted: Radboud University Medical Center, Modafinil + Placebo (NCT07582458)
- 2026-05-12Also stopped (terminated): University of Wisconsin, Madison, Psilocybin (NCT05322954)
- 2026-05-08Results posted on the registry: Corium, Inc., Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) (NCT05721235)
- 2026-05-05Also stopped (suspended): Cingulate Therapeutics, CTx-1301 - Dexmethylphenidate 6.25mg + CTx-1301 - Dexmethylphenidate 12.5mg (NCT05924594)
- 2026-04-15Results posted on the registry: University of Alabama at Birmingham, Algorithm Treatment (NCT03670316)
- 2026-02-27Also stopped (terminated): Luzerner Kantonsspital, a drug against SLC6A3 (NCT05192837)
- 2026-02-25Results posted on the registry: Abramson Cancer Center at Penn Medicine, a drug against SLC6A3 (NCT04798664)
- 2026-02-04Results posted on the registry: M.D. Anderson Cancer Center, Methylphenidate Hydrochloride + Therapeutic Melatonin (NCT01628029)
- 2026-02-02Results posted on the registry: Johns Hopkins University, Placebo + Methylphenidate (NCT03652740)
- 2026-01-29Results posted on the registry: Friends Research Institute, Inc., a drug against SLC6A3 (NCT03884946)
- 2026-01-28Results posted on the registry: Axsome Therapeutics, Inc., AXS-05 (dextromethorphan-bupropion) (NCT04634669)
- 2026-01-28Also stopped (terminated): Axsome Therapeutics, Inc., AXS-05 (dextromethorphan-bupropion) (NCT04634669)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision